394800.KQ 3billion
- Market cap
- KRW 170B
- P/E
- -
- P/B
- 5.74x
- ROE
- 35.4%
- Dividend yield
- -
- Fundamental score
- 1.6/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 394800.KQ undervalued?
Graham numberThe Graham number of 3billion cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
3billion fundamental analysis
7 of 22 checks passedROE 2/2
High return on equity (35.4%), above 20%.
ROA 1/1
Return on assets (17.9%) is above the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (17.8%) is above the industry median (4.8%).
Revenue Growth 2/2
Revenue grew 141.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 23.0x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (5.7x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
3billion stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 3billion
3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment. It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as well as provides various affiliated services to customers. The company was found…
Full company profile3billion financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
3billion annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 551M | 828M | 2.73B | 5.77B | 11.7B | 14.3B |
| Gross Profit | 551M | 479M | 1.76B | 4.10B | 11.7B | 14.3B |
| Operating Income | -6.70B | -8.22B | -8.35B | -7.42B | -5.89B | -6.66B |
| EBITDA | - | -2.17B | -3.60B | -4.86B | -3.27B | 13.2B |
| Net Income | -59.1B | -3.14B | -5.09B | -6.57B | -5.41B | 10.5B |
| EPS | -1,880 | -100 | -162 | -207 | -171 | 331 |
| Balance Sheet | ||||||
| Total Assets | 20.6B | 27.7B | 22.9B | 30.2B | 29.7B | 58.7B |
| Total Liabilities | 1.88B | 11.3B | 11.1B | 1.94B | 6.07B | 29.1B |
| Shareholders' Equity | 18.7B | 16.3B | 11.8B | 28.3B | 23.6B | 29.6B |
| Cash & Short-term Investments | 4.72B | 22.8B | 16.7B | 23.5B | 8.14B | 9.09B |
| Cash Flow | ||||||
| Operating Cash Flow | -4.63B | -6.41B | -4.87B | -4.10B | -3.56B | -7.50B |
| Capital Expenditure | 675M | 264M | 246M | 2.80B | 2.29B | 957M |
| Free Cash Flow | -5.31B | -6.68B | -5.12B | -6.90B | -5.85B | -8.45B |
| Ratios | ||||||
| ROE | -315.9% | -19.3% | -43.2% | -23.2% | -22.9% | 35.4% |
| ROA | -287.1% | -11.4% | -22.3% | -21.7% | -18.2% | 17.9% |
| Net Profit Margin | -10,733.5% | -379.6% | -186.5% | -113.9% | -46.2% | 73.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
3billion dividends
3billion has not paid dividends in the last 5 fiscal years.
Who owns 3billion
- Insiders 24.67%
- Institutions 5.36%
- Public & others 69.97%
- Shares outstanding 31.8M
- Free float 23.6M
3billion company profile
- Company name
- 3billion
- Ticker
- 394800.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 416 Teheran-ro, Seoul, South Korea, 06193
- Website
- 3billion.io
About 3billion
3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment. It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as well as provides various affiliated services to customers. The company was founded in 2016 and is based in Seoul, South Korea.
3billion management
1- Changwon KeumCEO & Representative Director